noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Georgia Department of Transportation

SR 400 Express Lanes Project Named Proximo North American Transport[...]
American Well Corporation

Statement of Changes in Beneficial Ownership (Form 4)
QXO Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

Healthcare

Rigel Pharmaceuticals Inc.

07/01/2026 | Press release | Distributed by Public on 07/01/2026 14:12

Management Change/Compensation (Form 8-K)

Item 5.02. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company. In connection with her appointment, Dr. Hannah resigned from the Company's Board of Directors (the "Board"), effective July 1, 2026.

Dr. Hannah had served as a member of the Board since May 2021. Since 2000, Dr. Hannah has served as a consultant to the pharmaceutical and biotechnology industry, directing the development of investigational cancer therapies. Prior to her consulting work, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc.

Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.

Rigel Pharmaceuticals Inc. published this content on July 01, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 01, 2026 at 20:12 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]